Cargando…

Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.

Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, A. L., Powles, T. J., Treleaven, J. G., Burman, J. F., Nicolson, M. C., Chung, H. I., Ashley, S. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977438/
https://www.ncbi.nlm.nih.gov/pubmed/1419616
_version_ 1782135261814063104
author Jones, A. L.
Powles, T. J.
Treleaven, J. G.
Burman, J. F.
Nicolson, M. C.
Chung, H. I.
Ashley, S. E.
author_facet Jones, A. L.
Powles, T. J.
Treleaven, J. G.
Burman, J. F.
Nicolson, M. C.
Chung, H. I.
Ashley, S. E.
author_sort Jones, A. L.
collection PubMed
description Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity.
format Text
id pubmed-1977438
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19774382009-09-10 Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Jones, A. L. Powles, T. J. Treleaven, J. G. Burman, J. F. Nicolson, M. C. Chung, H. I. Ashley, S. E. Br J Cancer Research Article Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months. There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short (maximum 36 months) and careful long term follow-up is necessary to detect clinically significant morbidity. Nature Publishing Group 1992-10 /pmc/articles/PMC1977438/ /pubmed/1419616 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Jones, A. L.
Powles, T. J.
Treleaven, J. G.
Burman, J. F.
Nicolson, M. C.
Chung, H. I.
Ashley, S. E.
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
title Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
title_full Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
title_fullStr Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
title_full_unstemmed Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
title_short Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
title_sort haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977438/
https://www.ncbi.nlm.nih.gov/pubmed/1419616
work_keys_str_mv AT jonesal haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen
AT powlestj haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen
AT treleavenjg haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen
AT burmanjf haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen
AT nicolsonmc haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen
AT chunghi haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen
AT ashleyse haemostaticchangesandthromboembolicriskduringtamoxifentherapyinnormalwomen